Intrinsiqs

Is Coherus Oncology, Inc. overvalued?

Coherus Oncology, Inc. (CHRS) — key valuation metrics and fundamentals.

No verdict
Price
$0.53
Fair value
—
Current P/E
—
Normal P/E
9.4
Market cap
$81.2M
Dividend yield
0.0%
Return on equity
-239.6%
Sector
Healthcare

See the full interactive analysis →

Fair value compares CHRS's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 12 Nov 2026.